The UK's drug regulator granted approval for Kisunla, an Alzheimer's medication, while an independent assessment body rejected its NHS funding on grounds of cost. The approval marks the second ...
Donanemab has been hailed as 'game changer' but the price tag has barred it from being available to nearly one million Brits.
Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.
The announcement comes as the UK's medicines regulator said that donanemab could be licensed for use in the UK.
About one in 10 people under 25 are unsure - or do not believe - that removing a condom during sex is a crime, according to a ...
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS in ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
7h
Donanemab has already been rejected in the NHS in England but Scottish Medicines Consortium has still to make a decision on ...
Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback